Changeflow GovPing Healthcare & Life Sciences Intestinal Ultrasound Predicts Crohn's Disease ...
Routine Notice Added Final

Intestinal Ultrasound Predicts Crohn's Disease Relapse in Deep Remission

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

NIH registered a multicenter prospective observational study evaluating transabdominal intestinal ultrasound as a non-invasive predictor of Crohn's disease relapse. The 18-month study will follow CD patients in deep remission, comparing color Doppler ultrasound parameters between relapse and non-relapse groups using stratified analysis by Montreal classification to establish a predictive model.

Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document registers a prospective observational clinical study with ClinicalTrials.gov. The study investigates whether transabdominal intestinal ultrasound can serve as a non-invasive, radiation-free alternative to endoscopy for predicting clinical relapse in Crohn's disease patients who have achieved deep remission. Researchers will compare color Doppler ultrasound parameters between patients who relapse and those who do not, using Montreal classification stratification to develop a predictive model.

Healthcare providers and clinical investigators involved in inflammatory bowel disease management may find the study's findings relevant to long-term monitoring protocols for Crohn's disease patients in deep remission.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study

Observational NCT07539727 Kind: OBSERVATIONAL Apr 20, 2026

Abstract

Crohn's disease (CD) is a nonspecific chronic inflammatory condition characterized by a protracted course with alternating periods of relapse and remission. Even patients who achieve deep remission remain prone to recurrence and require long-term follow-up. While various monitoring methods are available, endoscopy plays a primary role in the management and diagnosis of CD; however, its relative invasiveness and the need for bowel preparation limit the feasibility of continuous monitoring. In contrast, transabdominal intestinal ultrasound offers advantages such as non-invasiveness, absence of radiation, good patient tolerance, and low cost, making it suitable for long-term monitoring. However, most studies have focused on exploring its concordance with disease activity and endoscopic findings, with only a limited number of studies examining its clinical significance for long-term prognosis.

Therefore, we conducted a multicenter prospective study involving 18 months of follow-up in CD patients who achieved deep remission. Based on the follow-up results, patients were divided into relapse and non-relapse groups. Stratified analysis was performed according to the Montreal classification to compare color Doppler ultrasound parameters between the two groups and within each stratum, and to establish a predictive model.

Conditions: Inflammatory Bowel Diseases

Interventions: Transabdominal Intestinal Ultrasound

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 20th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical research Disease monitoring
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!